2月24日下午第二屆中歐國際對話-聚焦甲狀腺眼病熱點問題全球直播于南方醫(yī)科大學順德醫(yī)院完滿收官。南方醫(yī)科大學順德醫(yī)院院長、內(nèi)分泌與代謝科學科帶頭人沈潔教授擔任大會主席。大會特別邀請了意大利米蘭總醫(yī)院Graves眼病中心主任、歐洲Graves眼病專家小組（EUGOGO）指南負責人Mario Salvi馬里奧－薩爾維教授以及多名國內(nèi)知名內(nèi)分泌與代謝疾病專家、眼科專家線上線下參與直播。會上，馬里奧－薩爾維教授圍繞《ATA/ETA甲狀腺眼病共識》分別進行輕度、中重度甲狀腺眼病的診療進程，威脅視力甲狀腺眼病的處理及對策的深入解讀。上海交通大學醫(yī)學院附屬瑞金醫(yī)院內(nèi)分泌科主任王衛(wèi)慶教授圍繞“糖皮質激素治療甲狀腺眼病的循證醫(yī)學證據(jù)”話題進行經(jīng)驗分享；南京中醫(yī)藥大學附屬中西醫(yī)結合醫(yī)院內(nèi)分泌科副主任醫(yī)師劉洲君講解了“TAO眼眶內(nèi)注射療法”；中國醫(yī)科大學附屬第一醫(yī)院的李玉姝教授從一例極重的TAO患者的治療話題切入，帶來了深刻的思考；最后沈潔教授開展了“甲狀腺眼病威脅視力的評估預判”話題授課。大會每小節(jié)講解完畢，國內(nèi)外專家積極互動問答。Salvi教授始終在線上認真聽課，認真分析，耐心解答。整場全球直播氣氛熱烈，持續(xù)將近4個小時，直播間超4.3萬人次觀看。醫(yī)療無國界，服務無止境！非常感謝國內(nèi)外專家們毫無保留地分享了自己對甲狀腺眼病的診療經(jīng)驗和見解，以不懈的努力和敬業(yè)的精神為甲狀腺眼病診療的進步做出貢獻。期待通過國內(nèi)外專家的努力，為甲狀腺眼病患者提供更加高質量的醫(yī)療服務，造福眾多患者。

On the afternoon of February 24, the 2nd Sino-Euro Dialogue - Focus on Hot Topics of Thyroid Eye Disease Global Live Broadcast was successfully held at the Shunde Hospital of Southern Medical University. Prof. Shen Jie, the Medical Director of Shunde Hospital of Southern Medical University, Academic Leader of Endocrinology and Metabolism Division, served as the chairman of the conference. The conference specially invited Prof. Mario Salvi, Head of Graves' Orbitopathy Center from Fondazione Cà Granda Ospedale Maggiore Policlinico, and Guidelines Leader of EUGOGO as well as other renowned experts on Endocrinology and Metabolic Diseases and Ophthalmology at home to attend the broadcast online or offline. During the conference, Prof. Salvi gave a presentation which centered on "2022 Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association", and divided it into three parts, based on the management of mild, moderate-severe, and sight-threatening TED. Prof. Wang Weiqing, Director of Department of Endocrinology at Ruijin Hospital, Shanghai Jiaotong University School of Medicine shared her experience by delivering a lecture titled “The Evidence of Evidence-based Medicine in the Treatment of Thyroid Eye Disease with Glucocorticoids”; Liu Zhoujun, Deputy Chief Physician of Department of Endocrinology from the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine shared a lecture titled “Intraorbital Injection Therapy for TAO Patients”; Prof. Li Yushu, Chief Physician of Department of Endocrinology and Metabolic Diseases from the First Hospital of China Medical University began her speech by talking about the treatment of a patient diagnosed with very severe TAO, which was thought-provoking. In the end, Prof. Shen Jie gave a lecture on “Early Evaluation of Sight-Threatening Graves' orbitopathy”. After each part of the presentation was finished, experts at home and abroad actively interacted with each other. Prof. Salvi listened carefully online during the whole conference, and answered the questions from the Chinese experts actively and patiently. The webcast was in a warm atmosphere, lasting for about four hours and attracting over 43,000 online viewers. Countries have borders, but health care services don't. Great thanks go to experts at home and abroad who have shared their experience and insights on the treatment of TED without reservation and have made contributions to its advancement with arduous efforts and dedication. It is hoped that through their endeavor, more high-quality medical services will be provided for TED patients so as to benefit more of them.